Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 6/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860138 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7192624 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL800609 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL9774279 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL14296385 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL27859825 | 0.78 | NOS2 (0.42) | NOS2NOS3NOS1DPP4DPP8 | |
| D-Proline SCHEMBL16241649 | 0.77 | MEN1 (0.47) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL28678649 | 0.77 | MEN1 (0.47) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7400921 | 0.77 | NOS2 (0.41) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL28793427 | 0.77 | NOS2 (0.41) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889544-B2 | Ionic liquids comprising heteraromatic anions | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190031608-A1 | IONIC LIQUIDS COMPRISING HETERAROMATIC ANIONS | UNITED STATES DEPARTMENT OF ENERGY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889544-B2 | Ionic liquids comprising heteraromatic anions | PIP4K2C, PIP4K2A, PIP4K2B | NOS2 2340/4885NOS3 3109/4885NOS1 3705/4885 |
| US-20190031608-A1 | IONIC LIQUIDS COMPRISING HETERAROMATIC ANIONS | PIP4K2C, PIP4K2A, PIP4K2B | NOS2 2340/4885NOS3 3109/4885NOS1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.